Sorafenib-Daten auf dem Kongress 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO)

13. - 17. Mai 2005

Dienstag, 17. Mai:
Investoren-Telefonkonferenz ASCO Review 2005

Die Audio-Aufzeichnung dieser Veranstaltung ist nicht mehr verfügbar.

Fact Sheets und Hintergrundinformationen
(nur in Englisch verfügbar)
Sorafenib Clinical Program OverviewDownload PDF sammeln (120 KB)
Sorafenib Fact SheetDownload PDF sammeln (139 KB)
Renal Cell Carcinoma Fact SheetDownload PDF sammeln (114 KB)
Hepatocellular Carcinoma Fact SheetDownload PDF sammeln (138 KB)
Melanoma Fact SheetDownload PDF sammeln (119 KB)
Sorafenib at ASCO 2005Download PDF sammeln (119 KB)

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: LBA4510)

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: 4544 )

A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) ( Abstract No: 5566)

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients ( Abstract No: 7508)

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma ( Abstract No: 3037)

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) ( Abstract No: 3067)

Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma ( Abstract No: 3005)

Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: A prospective study ( Abstract No: 3069)

ASCO Homepage: www.asco.org

Informationen zu Klinischen Studien: www.clinicaltrials.gov

American Cancer Society: www.cancer.org

Informationen zu Nierenkrebs: www.cancer.gov/cancertopics/types/kidney

Informationen zu Leberkrebs: www.liverfoundation.org

Informationen zu Hautkrebs: www.melanomainternational.org

Informationen zu Häufigkeit, Prävalenz und Mortalität von Krebs (GLOBOCAN): www-dep.iarc.fr